I work in branding. In my job, I help brands find the distance between what they say they stand for and what they do, and then help them close it. That gap, when left open, is where trust goes to die.

Minnesota has a gap worth naming, and it is costing your organization money.

Minnesota ranks second in the nation for female labor force participation. We have paid family leave, strong unions, and health systems with mission statements that read like promises. And yet, comprehensive menopause coverage is left entirely to the discretion of individual insurers. No state mandate. No floor. No guarantee. 

That discretion is being used poorly, and not by one outlier. 

HealthPartners is the most instructive example. They are simultaneously an insurer, a care provider, and an employer with every financial and moral incentive to cover menopause care comprehensively, with published health equity commitments to match. However, their coverage policy tells a different story.

I know this from my own explanation of benefits. When my physician prescribed a compounded estradiol formulation, my HealthPartners plan initially denied it, triggering a prior authorization process that took hours of coordination between my doctor and the insurer before I could fill a prescription with settled clinical evidence behind it. While I got my prescription filled, I kept thinking about the women who don’t have the time, the physician support, or the persistence to wade through that process and who simply go without. A February 2026 Harris Poll survey of Americans with chronic conditions, commissioned by the PAN Foundation, found that 1 in 4 delayed treatment because of prior authorization requirements, 1 in 12 stopped treatment altogether, and more than 1 in 3 were told their authorization was approved only to have coverage denied after care was already provided. For those least able to fight it, prior authorization functions as a denial.

HealthPartners is not an anomaly. It is a case study in what happens when menopause coverage is treated as optional. 

HealthPartners cites evidence-based care as a cornerstone of its coverage decisions. But the women who don’t complete the process don’t generate claims data. Without claims data, there is no outcomes record. And without an outcomes record, the system never has to justify why the barriers existed in the first place. Boston Consulting Group (BCG) confirmed this pattern in a 2025 report: Estrogen therapies still carry obsolete warning labels that deter prescriptions, prior authorization requirements delay treatment, and coverage is routinely limited to monthly supplies for conditions requiring sustained management. The science moved. The administrative infrastructure did not.

The objection that compounded formulations lack standardized FDA approval misses the point. When a child cannot swallow a standard pill, physicians prescribe a compounded liquid version. And insurers cover it without hesitation. The FDA approval status of compounded estradiol is identical. The coverage decision is not. Compounded formulations in any form are prescribed when FDA-approved options have failed: wrong dosage, wrong delivery method, intolerable inactive ingredients. Requiring prior authorization for the compounded version, or denying it outright, is gatekeeping the solution to a problem the approved option created.

With coverage, hormone replacement therapy can cost as little as $10 for a three-month supply. Without it, the same treatment can exceed $500. That spread lands differently depending on what you earn, and the employer who thinks it isn’t their problem is wrong. It shows up in turnover, in reduced performance, and in the quiet career recalculations happening right now among your most experienced employees.

What Employers Are Losing 

The Mayo Clinic estimates that missed workdays alone cost the U.S. economy $1.8 billion annually. Boston Consulting Group puts the full cost, including downstream health care expenses borne by individuals and payers, at $26.6 billion. Both numbers capture only what can be measured: absenteeism, disability claims, and early retirement. It does not capture the woman who stays at her desk but cannot concentrate through the brain fog. The manager who stops putting herself forward for the high-visibility project because she does not trust her body to cooperate with the demands. The executive who quietly starts thinking about an exit she would not otherwise be considering.

A 2024 report from Carrot Fertility found that 32% of millennial women are already experiencing perimenopause symptoms, meaning the window of workforce impact begins far earlier than most employers recognize. Women at the height of their professional lives, with decades of experience and institutional knowledge, are navigating a significant physiological transition without support while their employers look the other way.

Nationally, 70% of millennial women say they would consider restructuring or leaving their careers to manage menopause based on a survey of women who have not yet reached menopause. That is a workforce crisis in formation, meaning the full cost of inaction has not been felt. BCG reports that approximately 20% of women already in menopause have left or considered leaving a job due to untreated symptoms. In a state where women work at the highest rates in the country, Minnesota’s share of that crisis is proportionally larger.

We are not saving money by not covering this. We are deferring costs while compounding harm.

Who Pays Most

The coverage gap does not distribute itself fairly. The women most likely to be denied claims are also the women earning the least—in jobs without robust employer plans, with physicians who don’t  have time to fight insurance appeals. The burden of an uncovered, undertreated transition falls hardest on the women who can least afford to carry it. 

Call it a gap. Call it an oversight. The women on the wrong side of it call it Tuesday.

What You Can Do 

Most Minnesota employers will need to have a conversation with their benefits broker or plan administrator this summer, before the next renewal.

Ask whether your current formulary covers compounded hormone therapies when a physician has prescribed them. Ask whether prior authorization requirements apply to treatments where FDA-approved options have failed the patient. And ask what it would cost to close the gap, then compare that number to what your organization spends recruiting and onboarding a single senior employee.

Comprehensive menopause coverage is a retention strategy for the people you can least afford to lose. It signals to younger women what your culture means when it costs something. It is available to you right now, in the next benefits negotiation.

The coverage gap is a choice. So is closing it.